Rheumatoid arthritis after human parvovirus B19 infection

Polyarthropathy associated with human parvovirus B19 (B19) is usually transient, but often resembles rheumatoid arthritis (RA).¹⁻³ However, B19 DNA screened by polymerase chain reaction (PCR) may be positive not only in autoimmune diseases, but also in non-arthropathy.⁴ To study whether or not RA occurs after acute B19 infection, we conducted a prospective study of patients with acute onset polyarthritis. Sixty seven cases showing acute inflammatory polyarthritis from January 1990 to June 1990 were examined and followed up for six years. Among them, 12 (9 female and 3 male) exhibited IgM anti-B19 antibodies.⁵ PCR, followed by a Southern blot analysis also showed the presence of B19 DNA in all 12 cases with IgM anti-B19 antibodies, but did not in the remainder. Initially, rheumatoid factor (RF) was negative in all B19 positive cases except one, but became positive in four, two to four months after the infection (table 1). Among RF positive cases, three (MI, RM, and TY) developed active polyarthropathy with destructive changes in the joints including fingers, wrists or elbows, and rheumatoid nodules. These patients were diagnosed as typical RA fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA as shown in table 2. No cases in the B19 negative group met the ACR criteria for RA during six years of follow up.

Figure 1 shows that B19 DNA was no longer detected in blood samples from the patients MI, RM, and TY four months after the initial episodes. It was, however, positive in bone marrow and synovial tissue. Both in situ hybridisation (ISH) and immunofluorescence (IF) study also revealed the presence of B19 DNA/RNA as well as VP-1 antigen in mononuclear cells of bone marrow samples (fig 2). Examination of peripheral mononuclear cells by the stimulation with B19 antigen, showed significantly higher proliferative responses to recombinant VP-1 in patients MI, RM, and TY compared with others (p<0.002).

Clinically, three patients with RA were in an active stage and, therefore, treated with a high dose (20 g/day) of gammaglobulin for 10 days (fig 1) after a variety of anti-rheumatic drugs including gold, D-penicillamine or methotrexate became ineffective. The treatment caused a reduction in multiple joint pain and swelling, and a decrease in the C reactive protein value (from 0.8 to 0.3 for patient MI and from 3.6 to 2.0 for patient RM). The number of VP-1 positive cells in bone marrow markedly decreased after the treatment (from 3.6% or 2.6%, to undetectable values or 0.5% in MI and RM respectively).

Table 1 Prevalence of joint involvement and RF after the initial episode

<table>
<thead>
<tr>
<th>Clinical finding</th>
<th>Group*</th>
<th>No of positive cases/no of total cases</th>
<th>Initial episode</th>
<th>4 months after</th>
<th>6 years after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint pain</td>
<td>B19 negative</td>
<td>52/52 (100)</td>
<td>4/52 (7.7)**</td>
<td>2/52 (3.6)**</td>
<td></td>
</tr>
<tr>
<td>Joint pain</td>
<td>B19 positive</td>
<td>12/12 (100)</td>
<td>4/12 (33.3)**</td>
<td>4/12 (33.3)**</td>
<td></td>
</tr>
<tr>
<td>Positive RF</td>
<td>B19 negative</td>
<td>3/52 (5.8)</td>
<td>3/52 (5.8)**</td>
<td>3/52 (5.8)**</td>
<td></td>
</tr>
<tr>
<td>Postive RF</td>
<td>B19 positive</td>
<td>1/12 (8.3)</td>
<td>5/12 (41.6)**</td>
<td>4/12 (33.3)**</td>
<td></td>
</tr>
</tbody>
</table>

*Each group was divided into two groups based on the evidence of IgM anti-B19 antibody at beginning of the study. **p<0.01.

Table 2 Profile of patients who developed RA after acute B19 infection

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Sex</th>
<th>Morning stiffness</th>
<th>Arthritis of three or more joint areas</th>
<th>Symmetric arthritis</th>
<th>Arthritis of hand joints</th>
<th>Serum rheumatoid factor</th>
<th>Radiographic changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Male</td>
<td>++</td>
<td>+ (10)*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>42</td>
<td>Female</td>
<td>++</td>
<td>+ (14)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>44</td>
<td>Male</td>
<td>++</td>
<td>+ (9)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*Number of affected joints.

Figure 1 Clinical course of patients MI (A) and RM (B). MTX; methotrexate, CRP; C reactive protein, ESR; erythrocyte sedimentation rate, RF; rheumatoid factor.
The prevalence of IgM anti-B19 antibodies in this area was below 0.1% at the time of the study, and so far we have not obtained the evidence of B19 DNA/RNA and VP-1 antigens in the bone marrow samples from patients with haematological diseases, when screened by ISH and IF. The patients in this study developed RA with destructive changes in the joints after acute B19 infection, and had the evidence of persistent activation of B19 in vivo, as demonstrated in a subject with recurrent episodes of B19 infection. The decrease of B19 positive cells in bone marrow and their clinical improvement subsequent to intravenous immunoglobulin therapy also supports our view of a relation between B19 infection and polyarthritis, as indicated in the case with a recovery from B19 associated pure red cell aplasia after immunoglobulin therapy. Furthermore, the transfection of NS-1 gene of B19 has been shown to induce an increased IL6 production in vitro. Our results indicate that B19 should be investigated in association with the aetiopathogenesis of RA.

CHIHIRO MURAI
YASUHIKO MUNAKATA
YUICHI TAKAHASHI
TOMONORI ISHII
SHINOBU SHIBATA
TAI MURYOI
TADAO FUNATO
MASATAKA NAKAMURA
KAZUO SUGAMURA
TAKESHI SASAKI

The Second Department of Internal Medicine, Bacteriology, Clinical and Laboratory Medicine, Tohoku University School of Medicine, Sendai, 980 Japan

Correspondence to: Dr T Sasaki.

7 Amett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria


